The fed futures priced that out to july instead of june. If you look at treasury yields, there was a 10basis point jump in the tenyear yield. 4. 27. The twoyear yield at 4. 68. Looking at the hotterthan expected Producer Prices for two months whand hotter consumer prices, it makes you won beder t you see with inflation. The price of bitcoin as we talked about that before we came on it never closes. You never know to base the change. That change doesnt tell you what is happening. Here is the range from yesterday. I can look at coinbase where i watch it. The high was 73,418. We say that. The low was 65,500 i did some math. Thats 8,000 on a 73,000 stock. More than 10 . If you decide you want to tread into this, be ready to buy at 73 and wake up the next morning to see it at 65. The weird thing about it, gold and bitcoin is supposed to go up with inflation. When inflation is running, it means the fed will not cut. They will not print. Liquidity play. They will not print and everybody wants
Frazier Life Sciences Management L.P. bought a new position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 69,406 shares of the biopharmaceutical company’s stock, valued at approximately $16,059,000. Frazier Life Sciences […]
Paulson & CO. Inc. increased its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 121.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,105,741 shares of the biopharmaceutical company’s stock after purchasing an additional 605,741 shares during the quarter. Madrigal […]
Bain Capital Life Sciences Investors LLC bought a new stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 324,619 shares of the biopharmaceutical company’s stock, valued at approximately $75,110,000. Madrigal Pharmaceuticals comprises approximately […]
Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) was upgraded by research analysts at StockNews.com to a “sell” rating in a research report issued to clients and investors on Wednesday. Other equities research analysts also recently issued research reports about the company. Piper Sandler restated an “overweight” rating and set a $336.00 price target on shares […]